Lineage Cell Therapeutics (XTAE:LCTX) 3-Year ROIIC % : 21.35% (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Lineage Cell Therapeutics 3-Year ROIIC %?

3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year. Lineage Cell Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 was 21.35%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Lineage Cell Therapeutics's 3-Year ROIIC % or its related term are showing as below:

XTAE:LCTX's 3-Year ROIIC % is ranked better than
69.5% of 1423 companies
in the Biotechnology industry
Industry Median: -14.56 vs XTAE:LCTX: 21.35

Lineage Cell Therapeutics 3-Year ROIIC % Historical Data

The historical data trend for Lineage Cell Therapeutics's 3-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics 3-Year ROIIC % Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

3-Year ROIIC %

Get a 7-Day Free Trial

-117.35

-23.51

-37.94

-6.22

21.35

Lineage Cell Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
3-Year ROIIC %	Get a 7-Day Free Trial															-	-	-	21.35	-

Competitive Comparison of Lineage Cell Therapeutics's 3-Year ROIIC %

For the Biotechnology subindustry, Lineage Cell Therapeutics's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lineage Cell Therapeutics's 3-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's 3-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's 3-Year ROIIC % falls into.

Lineage Cell Therapeutics 3-Year ROIIC % Calculation

Lineage Cell Therapeutics's 3-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

3-Year ROIIC %	=	3-Year Incremental Net Operating Profit After Taxes (NOPAT)^**	/	3-Year Incremental Invested Capital^**
	=	( -84.3219496 (Dec. 2023) - -92.208255 (Dec. 2020) )	/	( 285.985 (Dec. 2023) - 249.054 (Dec. 2020) )
	=	7.8863054	/	36.931
	=	21.35%^***

** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.

Lineage Cell Therapeutics (XTAE:LCTX) 3-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.

Lineage Cell Therapeutics 3-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's 3-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics (XTAE:LCTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (XTAE:LCTX) » Definitions » 3-Year ROIIC %

Comparable Companies

Traded in Other Exchanges

LCTX:USA BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.